RCS - Ondine Biomedical - Ondine and Mid Yorks Win National Award

Ondine BiomedicalAnnouncement

06/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260206:nRSF9683Ra&default-theme=true

RNS Number : 9683R  Ondine Biomedical Inc.  06 February 2026

6 February 2026

 

ONDINE BIOMEDICAL INC.

 

("Ondine Biomedical", "Ondine", or the "Company")

 

 

Ondine and Mid Yorks Win National Award

Excellence in Healthcare Partnership Award recognises proven collaboration
delivering significant SSI reductions and supporting NHS priorities

 

Ondine Biomedical Inc. (AIM: OBI) and Mid Yorkshire Teaching NHS Trust ("Mid
Yorks") have won the Excellence in Healthcare Partnership Award in the
Partnership Working to Address National Healthcare Priorities (Local Projects)
category, recognising their collaboration to significantly reduce surgical
site infections (SSIs) using Ondine's Steriwave® nasal photodisinfection
technology.

The winning initiative follows the successful pilot and ongoing introduction
of Steriwave nasal photodisinfection into orthopaedic surgery pathways at Mid
Yorks in 2024. Implemented for patients undergoing hip and knee replacement
surgery, the intervention was associated with a 71% reduction in post-surgical
infections in hip surgery, with no SSIs observed in knee surgery during the
evaluation period. In addition to improving patient outcomes, the programme
delivered meaningful cost savings by reducing avoidable complications and
associated hospital resource use.

Since the initial implementation at Mid Yorks, Steriwave is now being used or
evaluated by several major hospitals across England in a range of surgical
specialties, as well as in intensive care following cardiac surgery. Adoption
has been driven in part by increasing concern over antibiotic resistance and
poor patient compliance, which limit the effectiveness of typical
antibiotic-based nasal decolonisation. Unlike antibiotics, photodisinfection
rapidly destroys bacteria, viruses and fungi without generating resistance,
offering an immediately effective alternative that supports long-term
antimicrobial stewardship and lowers post-surgical infection rates.

Carolyn Cross, CEO of Ondine, commented:

"Winning this national award is a powerful validation of what can be achieved
when NHS clinicians and industry partners work together to tackle real-world
challenges. This recognition reflects not only the strength of our partnership
with Mid Yorkshire, but also the growing acknowledgement that non-antibiotic
innovations like Ondine's photodisinfection technology can play a vital role
in improving patient safety, reducing avoidable complications and supporting
the sustainability of healthcare systems."

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation
at Mid Yorkshire Teaching NHS Trust, added:

"This award recognises the impact of a collaboration focused squarely on
patient safety and clinical outcomes. Reducing surgical site infections is
critical for patients and for the NHS, and we are proud that our work with
Ondine has been recognised nationally as an example of how innovation can be
successfully integrated into routine care."

The award, announced at the 2026 Excellence in Healthcare Partnership (EHP)
Awards ceremony, celebrates partnerships between the NHS and industry that
deliver measurable improvements in patient safety, system efficiency and
antimicrobial stewardship. The Ondine-Mid Yorks collaboration was recognised
for addressing one of the NHS's most urgent challenges of reducing SSIs while
limiting reliance on antibiotics.

Ondine and Mid Yorks have also been shortlisted as a finalist for the HSJ
Partnership Awards in the category Most Impactful Use of Technology on
Clinical Practice, reinforcing the growing momentum behind photodisinfection
as a practical, non-antibiotic approach to infection prevention within the
NHS. Winners of the HJS Partnership Awards will be announced at the awards
ceremony on 19 March 2026.

For healthcare providers in the UK interested in Steriwave®, the technology
is available through Ondine's distribution partner, Mölnlycke Health Care, a
global leader in medical solutions. For more information contact: Healthcare
Professionals Contact or info.uk@molnlycke.com, or call +44 0800 917 4918.

 

Enquiries:

 Ondine Biomedical Inc.                                www.ondinebio.com (http://www.ondinebio.com/)
 Carolyn Cross, CEO                                    +1 604 669 0555

or via Vane Percy & Roberts
 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                         +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                         +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                      +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico and several other
countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns, and other indications.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADDGDDIDGDGLU



            Copyright 2019 Regulatory News Service, all rights reserved